Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 09, 2021 at 08:03 am EDT
Share
Guilin Sanjin Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 879.904 million compared to CNY 752.252 million a year ago. Operating income was CNY 293.339 million compared to CNY 283.349 million a year ago. Net income was CNY 247.192 million compared to CNY 241.251 million a year ago. Basic earnings per share from continuing operations was CNY 0.43 compared to CNY 0.42 a year ago.
Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.
GUILIN SANJIN PHARMACEUTICAL CO., LTD. 
